Milestone Pharmaceuticals Inc.
MIST

$95.99 M
Marketcap
$1.80
Share price
Country
$0.09
Change (1 day)
$2.93
Year High
$1.12
Year Low
Categories

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

marketcap

Earnings for Milestone Pharmaceuticals Inc. (MIST)

Earnings in 2023 (TTM): $-59,685,000

According to Milestone Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-59,685,000. The earnings displayed on this page is the company's Pretax Income.

Earnings history of Milestone Pharmaceuticals Inc.

Annual Earnings

Year Income Before Tax Net Income
2023 $-59,685,000 $-59,685,000
2022 $-58,388,000 $-57,134,000
2021 $-42,853,000 $-42,633,000
2020 $-49,984,000 $-49,967,000
2019 $-55,285,000 $-55,229,000
2018 $-23,111,000 $-23,185,000
2017 $-8,082,000 $-8,086,000